Adaptimmune Announces Delisting from Nasdaq and Deregistration from the Securities Exchange Act of 1934.

Adaptimmune Therapeutics announced the delisting of its American Depositary Shares from Nasdaq and deregistration under the Securities Exchange Act of 1934. The decision was made following a transaction with US WorldMeds and the restructuring of the company to maximize value. The delisting is expected to facilitate cost reductions and the goal of maximizing value from remaining assets. Trading of Adaptimmune's ADSs will be suspended on or about October 27, 2025, and they will be quoted on the OTC Pink Limited Market.

Adaptimmune Therapeutics Plc (NASDAQ: ADAP) has announced its decision to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister its securities under the Securities Exchange Act of 1934. The move comes after a significant transaction with US WorldMeds and ongoing restructuring efforts aimed at maximizing value from the company's remaining assets.

The delisting decision was authorized by the company's Board of Directors on October 15, 2025, with trading of its ADSs expected to be suspended after the market close on or around October 27, 2025. Adaptimmune plans to file the necessary Form 25 with the Securities and Exchange Commission (SEC) on or about October 28, 2025, to formalize the delisting process.

Adrian Rawcliffe, CEO of Adaptimmune, stated that the delisting and deregistration will help reduce costs associated with SEC filings, Sarbanes-Oxley compliance, and Nasdaq listing requirements. "The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward," Rawcliffe explained.

Following the delisting, the company expects its shares may trade on the OTC Pink Limited Market, although it acknowledged there is no guarantee that broker support or trading will continue. Adaptimmune intends to file a Form 15 with the SEC after delisting to suspend its reporting obligations, citing fewer than 300 shareholders of record.

The Board determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages, pointing to significant costs related to SEC filings, legal and audit expenses, and management time demands under various regulatory requirements.

Adaptimmune completed its transaction with US WorldMeds on July 31, 2025, and continues efforts to maximize value from its remaining assets, including programs targeting PRAME and CD70. The company expects its ADSs may be quoted on the OTC Pink market but warned there is no guarantee a broker will continue to make a market.